Results. 1289 ITT patients were randomized (LEE n = 646; MOX, n = 643). Most patients in both groups achieved ECR at Day 3, with further increases through Day 7 and sustained efficacy through LFU (Fig 1). In mITT patients, IACR success rates at EOT/TOC/ LFU were 87.1/85.0/83.2% with LEE and 88.1/87.1/86.1% with MOX; results were consistent in CE patients. The proportions of ITT patients with resolution of all baseline signs/symptoms of CABP increased similarly by visit in both treatment groups (Fig 2). Most patients did not achieve complete sign/symptom resolution until TOC, with fever generally being the first and cough the last to resolve. There was no apparent relationship between ECR and age, gender, renal status, SIRS, PORT, prior antibiotic use, baseline pathogens, typical/atypical pathogens, or mono/polymicrobial pathogens. The high percentage of patients at LFU with baseline symptom resolution suggests that symptom resolution was sustained.

Conclusion. In this pooled analysis, efficacy results were similar by visit in the LEE and MOX groups, with high ECR rates maintained through LFU. LEE will provide a potential new effective systemic monotherapy alternative to fluoroquinolones for the empiric treatment of CABP.

Disclosures. All authors: No reported disclosures.

2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)

Andrzej Madej, MD1; John Pullman, MD2; Monica Popescu, MD3; Megan Quintas, BS4; Laura Lawrence, BS5; Yang Li6; Sue Cammarata, MD7; Andrzej Frycz Modrzewski Krakow University Faculty of Medicine and Health Sciences, Cracow, Malopolskie, Poland; 2; Mercury Street Medical, Butte, Montana; 3; Saint Pantelimon Emergency Clinical Hospital, Bucharest, Dambovita, Romania; 4; Melinta Therapeutics, Inc., Morristown, New Jersey; 5; Firma Clinical, Huntsville, Maryland; 6; Melinta Therapeutics, Morristown, New Jersey

Session: 245. Bacterial Respiratory Infections
Saturday, October 5, 2019: 12:15 PM

Background. Delafloxacin (DLX) is a fluoroquinolone, approved in the United States for treatment of ABSSSI. DLX has no preclinical signals for QT prolongation and has no QT prolongation in a validated challenge study. Risk of QT prolongation is a consideration in antibiotic selection for elderly hospitalized CABP patients. A Phase 3 CABP trial with DLX was analyzed with a focus on age and gender.

Methods. Data on age and gender were reviewed from a multicenter, randomized, double-blind trial of adults with CABP. Patients were randomized 1:1 to DLX or moxifloxacin (MOX) treatment for 5–10 days. Patients received a minimum of 3 days of IV treatment, then were switched to oral at MD discretion. A key clinical endpoint was the investigator-assessment at Test of Cure (TOC) 5–10 days after the end of treatment. Clinical success was defined as complete or near resolution of signs and symptoms and no further antibiotics needed.

Results. In the overall study, 859 patients were randomized with a mean age of 60 years (55.5% <65, 44.5% ≥65; 21.2% ≥75; range 18–93); 58.7% were male; 25.4% and 1.4% were PORT class IV and V; 28.6% multi-lobo pneumonia. Table shows the comparison of DLX and MOX clinical response at TOC in the Intent to Treat (ITT) population. Overall, DLX was well tolerated, with similar related adverse events (AE) between treatment groups regardless of age (< 65: 16.7% DLX, 13.3% MOX ≥65: 13.4% DLX, 11.7% MOX) or gender (male: 16.0% DLX, 11.1% MOX; female 14.0% DLX, 14.9% MOX). The most common treatment-related AEs for DLX were diarrhea and transaminase elevations which were mild-to-moderate and did not routinely lead to discontinuation. There were no reports of potential QT prolongation on DLX.

Conclusion. Based on age and gender, DLX had comparable outcomes to MOX in clinical success at TOC. DLX was also well tolerated regardless of age or gender. DLX may offer a promising alternative in the treatment of CABP including elderly patients.

Disclosures. All authors: No reported disclosures.

2235. Fecal Biomarkers for Clostridioides difficile Infection in Cancer Patients

Adilene Olvera, MPH MLS (ASCP)1; Eduardo Yepes Guevara, MD2; Kevin W. Garey, PharmD, MS, FASHIP3; Ryan J. Dillon, MSc4; Pablo C. Okhuysen, MD, FAPCR, FIDSA5; The University of Texas MD Anderson Cancer Center, Houston, Texas; 2; University of Houston College of Pharmacy, Houston, Texas; 3; Merck & Co., Inc., Kenilworth, New Jersey

Session: 245. Bacterial Respiratory Infections
Saturday, October 5, 2019: 12:15 PM

Background. The diagnosis of C. difficile infection (CDI) relies on using a nucleic acid amplification test (NAAT) followed by confirmatory toxin enzyme immunoassay (EIA). This study examined the utility of fecal biomarkers and C. difficile bacterial quantity (BQ) in differentiating patients with true infection (NAAT+EIA+) from patients with colonization (NAAT+EIA−) in the context of C. difficile ribotypes.

Methods. We studied 136 patients with diarrhea and CDI identified by NAAT in stools for which a confirmatory toxin A, B, EIA was performed. Fecal IL-8, IL-1β, calprotectin, and lactoferrin were studied by ELISA. C. difficile BQ was determined by 16S rRNA qPCR. Data were stratified according to cancer diagnosis into three groups [hematologic (H) n = 43, solid tumor (ST) n = 62, or stem cell transplant (SCT) n = 31].

Results. Stools were EIA+ in 36/136 (26%) of the cohort. Although ST patients had a higher Charlson co-morbidity index when compared with the other two groups (P < 0.002), demographic characteristics and symptoms at the time of presentation were similar between groups regardless of EIA status. Most common ribotypes identified included F106 and F104-020. Ribotype distribution differed according to oncologic diagnosis as determined by the Shannon diversity index. There were fewer distinct C. difficile ribotypes in the SCT (n = 8) vs. ST (n = 15) and H (n = 13) groups (P < 0.001 and P < 0.002, respectively). BQ were higher in EIA+ than EIA− across all strata (log of BQ/mg wet weight 2.38 ± 1.49 vs. 0.92 ± 1.28, P < 0.001). Similarly, higher levels of fecal IL-8 (1.72 ± 1.9 vs. 0.83 ± 1.6 ng/mL), IL-1β (3.74 ± 1.37 vs. 2.12 ± 4.6) and calprotectin (14.97 ± 2.7 vs. 6.1 ± 8.6 μg/mL) levels were seen in EIA+ patients. While IL-8, IL-1β, and calprotectin were increased in EIA+ ST and H, no differences were seen in the SCT group. A sensitivity analysis using ROC curves, revealed that BQ resulted in a greater area under the curve than fecal markers of inflammation (A = 0.77, P < 0.001, 95% CI [0.67–0.86]).

Conclusion. In this study in cancer and immunocompromised patients, C. difficile bacterial burden regardless of infecting ribotype and fecal cytokines showed to be a helpful assay in distinguishing true CDI from colonization.

Table 1: Clinical presentation by Oncological Diagnosis Group

| Cancer Type | Hematological | Solid Tumor | SCT | P value |
|-------------|---------------|-------------|-----|---------|
| Community Associated | 42 (68) | 51 (86) | 31 (100) | 0.000 |
| Healthcare Facility Associated (within 12 wks post discharge) | 6 (14) | 7 (11) | 7 (20) | 0.891 |
| Healthcare Facility Associated (outside of 12 wks post discharge) | 18 (42) | 21 (34) | 3 (10) | 0.891 |
| Median (interquartile range) | 16 (9) | 20 (15) | 16 (9) | 0.001 |
| Chemotherapy | 30 (60) | 30 (60) | 27 (87) | > 0.001 |

Poster Abstracts • OFID 2019:6 (Suppl 2) • 5763